- Home
- PLX vs ANTX Comparison
PLX vs ANTX Comparison
Compare PLX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | ANTX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 172.9M |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PLX | ANTX |
|---|---|---|
| Price | $2.76 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 767.5K | 287.5K |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $1.00 |
| 52 Week High | $3.19 | $7.19 |
Technical Indicators
Market Signals| Indicator | PLX | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 26.46 |
| Support Level | $2.59 | $1.02 |
| Resistance Level | $2.85 | $5.21 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 73.83 | 0.24 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.